The support you and your patients need—every step of the way.

OneSource™ offers education, assistance with access to SOLIRIS®, and ongoing treatment support for patients with PNH and patients with atypical HUS†, as well as the healthcare professionals who take care of them.
OneSource™ provides one-on-one support for you and your patients living with PNH or atypical HUS†.

OneSource® is a program that provides education, assistance with access to SOLIRIS®, and treatment support for people living with PNH or atypical HUS†, their caregivers and their healthcare providers.

The OneSource program is staffed with experienced Nurse Case Managers with in-depth knowledge of PNH and atypical HUS† and expertise in healthcare reimbursement. Upon enrollment, patients are assigned a Nurse Case Manager who will be their primary contact throughout their treatment journey.

**OneSource offers a personalized approach to treatment support.**

The Nurse Case Managers at OneSource help to make the process easier for physicians and are dedicated to addressing each patient’s individual needs. As a result, OneSource provides a wide range of services to all patients with PNH or atypical HUS†, while maintaining patient confidentiality.

**PHYSICIAN AND PATIENT SUPPORT**

- Coordination of drug shipment and delivery
- Coordination of clinic and home infusion services
- Nursing telephone support including after-hours and weekend support
- Post-infusion reports sent back to the physician
- Prescription renewal and vaccination reminders
- Patient education on disease and treatment
- Meningococcal vaccination services
- Pharmacovigilance reporting
- Appointment scheduling management

**REIMBURSEMENT ASSISTANCE**

- Navigation of all avenues of reimbursement to ensure maximum coverage for SOLIRIS
- Coordination of co-pay support
- Facilitation of all follow-ups with payers to minimize any challenges in reimbursement for both healthcare professionals and patients
- Monitoring of coverage renewals to avoid any interruption in SOLIRIS treatment
- In-office reimbursement support by a nurse or reimbursement expert for physicians

**NURSING SERVICES**

- Nurse Case Managers can assist in coordinating home infusion services
- OneSource™ has a network of 55 private ambulatory community clinics across Canada to support physicians with the administration of SOLIRIS® to their patients

**PHARMACY SERVICES**

- Direct-to-home and clinic drug delivery services
- Pharmacy and distribution coordination available across the country
- OneSource has an exclusive network of over 200 experienced nurses across the country with in-depth knowledge of PNH and atypical HUS†, who have experience in the pharmaceutical and biotechnology sectors, and are trained in the provision of specialty services to patients, their caregivers and healthcare providers
- Expertise in the unique requirements related to specialty medications
- The OneSource pharmacy is seamlessly integrated with the distribution centre

---

**Personalized support for you and your patients!**

OneSource™ provides education, assistance with access to SOLIRIS®, and treatment support for patients living with PNH or atypical HUS†, their caregivers and their healthcare providers.

Contact OneSource to obtain time-saving assistance.

**1.888.SOLIRIS (1.888.765.4747)** Monday—Friday 8AM to 8PM EST

Nurse Case Manager

Cell Phone #

*Funded by Alexion Pharma Canada.
Helping patients get access to SOLIRIS® need not be complicated.

Support is only a phone call away.

• OneSource™ Nurse Case Managers are available every day of the year, with after-hours and weekend direct line assistance, to help answer questions and offer support designed for you and your patients’ needs.

• OneSource is a no-charge program that provides education, access to SOLIRIS, and ongoing treatment support for people living with PNH or atypical HUS†, their caregivers and their healthcare providers.

• The OneSource program is staffed with experienced Nurse Case Managers with in-depth knowledge of PNH and atypical HUS† and expertise in healthcare reimbursement.

Contact OneSource to obtain time-saving assistance with education, access to SOLIRIS, and treatment support.

☎ 1.888.SOLIRIS (1.888.765.4747) ☉ Monday—Friday 8AM to 8PM EST

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

SOLIRIS increases the risk of meningococcal infections. Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early.

• Comply with the most current National Advisory Committee on Immunization (NACI) recommendations for meningococcal vaccination in patients with complement deficiencies.

• All patients must be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS, unless the risks of delaying SOLIRIS therapy outweigh the risks of developing a meningococcal infection; revaccinate according to current medical guidelines for vaccine use.

• All patients must be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics, if necessary.

• Vaccination may not prevent all meningococcal infections.

†SOLIRIS® has been issued marketing authorization for atypical HUS in adults and adolescents. SOLIRIS® has been issued marketing authorization with conditions (NOC/c) for atypical HUS in children <13 years of age and/or weighing <40 kg.